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Cimetidine, a H2 receptor antagonist, has been reported to improve survival in gastrointestinal cancer patients. These effects
have largely been attributed to the enhancing effects of cimetidine on the host’s antitumour cell-mediated immune response,
such as inhibition of suppressor T lymphocyte activity, stimulation of natural killer cell activity and increase of interleukin-2
production from helper T lymphocytes. We conducted an in vitro study on the effects of cimetidine on differentiation and
antigen presenting capacity of monocyte-derived dendritic cells from advanced colorectal cancer patients and normal controls.
As a result, an investigation of expression of surface molecules associated with dendritic cells by ﬂow cytometric analyses
showed that cimetidine had no enhancing effect on differentiation of dendritic cells from cancer patients and normal controls.
An investigation of [
3H]thymidine incorporation by allogeneic mixed lymphocyte reactions revealed that cimetidine increased
the antigen presenting capacity of dendritic cells from both materials. Moreover, a higher antigen presenting capacity was
observed in advanced cancer patients compared to normal controls. These effects might be mediated via speciﬁc action of
cimetidine and not via H2 receptors because famotidine did not show similar effects. Our results suggest that cimetidine may
enhance the host’s antitumour cell-mediated immunity by improving the suppressed dendritic cells function of advanced
cancer patients.
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Cimetidine, a histamine type 2 (H2) receptor antagonist, widely used
to treat peptic ulcers, has also been shown to have clinical beneﬁts in
cancerpatients.Itwasﬁrstreportedin1988thatapostoperativecourse
of cimetidine improved survival in gastric cancer patients (Tonnesen
et al, 1988). Since then, several studies have been published showing
major survival advantages in gastrointestinal cancer patients treated
with cimetidine (Adams and Morris, 1994; Matsumoto, 1995; Kelly
et al, 1999). Many studies on the mechanisms of this action have indi-
catedthattheantitumoureffectsofcimetidinemightbeduetoadirect
inhibitory effect on tumour growth (Adamsand Morris, 1994; Adams
et al, 1994; Reynolds et al, 1996), cell-mediated immunomodulation
(Osband et al, 1981; Hellstrand and Hermodsson, 1986; Gifford and
Tirberg, 1987), or inhibition of cancer cell metastases (Kobayashi et
al, 2000). The mechanisms proposed for cell-mediated immunomo-
dulation of cimetidine include inhibition of suppressor T
lymphocyte activity (Osband et al, 1981), stimulation of natural killer
(NK)cellactivity(HellstrandandHermodsson,1986),andincreaseof
interleukin-2 (IL-2)production in helperTlymphocytes (Gifford and
Tirberg, 1987).
Dendritic cells (DC), which are potent antigen presenting cells
capable of priming naive T lymphocytes and subsequently inducing
cytotoxic T lymphocytes (CTL) by stimulation of Th1 type
immune response, play a central role in cell-mediated immunity
(Janeway et al, 1997; Banchereau and Steinman, 1998). With the
recent development of culture methods for propagating DC on a
large scale from human peripheral blood mononuclear cells
(PBMC) (Caux et al, 1992; Sallusto and Lanzavecchia, 1994), vacci-
nation aimed at efﬁcient production of CTL with tumour-antigen-
loaded DC represents a potentially powerful strategy to induce
tumour rejection (Young and Inaba, 1996; Nestle et al, 1998).
Moreover, since it has also been reported that DC stimulate NK
cell activity (Fernandez et al, 1999; Yu et al, 2001), DC should
be considered to be associated intimately with not only the produc-
tion of CTL but also with the whole process of antitumour cell-
mediated immunity. However, there is little published information
regarding the inﬂuence of cimetidine on DC function.
Based on the above-mentioned ﬁndings, it was reported recently
that histamine inhibits the secretion of human interleukin-12 (IL-
12) via H2 receptors expressed on monocytes (precursors of DC),
and these effects of histamine can be reversed by H2 receptor antago-
nists such as cimetidine (Elenkov et al, 1998; Tineke et al, 1998).
In the present study, we assumed that cimetidine might have
some inﬂuence on monocyte-derived DC functions via H2 recep-
tors and investigated the effects of cimetidine on in vitro (1)
differentiation, (2) antigen presenting capacity, and (3) IL-12
production of monocyte-derived DC from colorectal cancer
patients and normal controls.
MATERIALS AND METHODS
Patients and controls
The study has been carried out with the ethical committee
approval. Ten patients (four men and six women) with advanced
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years) were studied (Table 1). All tumours were classiﬁed as stage
IV according to tumour-node-metastasis (TNM). All patients had
received chemotherapy and/or operation and had the interval of
more than 4 weeks prior to the present study. Their leukocyte
numbers were within normal limits. The control subjects consisted
of 10 age-matched healthy volunteers (eight men and two women).
All patients and all healthy volunteers were free from infection and
other complications at the time of study.
Media and reagents
RPMI 1640 supplemented with 4 mML -glutamine and NaHCO3
(Nikken, Kyoto, Japan), 100 IU ml
71 penicillin and 100 mgm l
71
streptomycin (Sigma, UK), 50 mM 2-mercaptoethanol, and 10%
heat-inactivated foetal calf serum (FCS) was used as culture
medium throughout the experiments. Human recombinant granu-
locyte macrophage-colony stimulating factor (GM-CSF) and
interleukin-4 (IL-4) were kindly provided by Kirin Brewery
(Gunma, Japan) and Genzyme (Minneapolis, MN, USA), respec-
tively. Cimetidine and famotidine were kindly provided by Smith
Kline Beecham, Japan (Tokyo, Japan) and Yamanouchi (Tokyo,
Japan), respectively.
Generation of DC
PBMC were obtained from 10 patients with advanced colorectal
cancer by leukapheresis using Blood Cell Separator CS-3000
TM
(Baxter, Deerﬁeld, IL, USA) after informed consent was obtained.
As control subjects, PBMC from healthy volunteers were prepared
by density gradient centrifugation on Ficoll-Hypaque Plus (Phar-
macia Biotech, Sweden). Interphases were harvested and washed
twice with RPMI 1640 at low speed to remove platelets. Monocytes
were separated from these PBMC by plastic dish adhesion for 2 h
at 378C in a 5% CO2 atmosphere and were further incubated for 7
days at 378C in culture medium supplemented with 500 U ml
71 of
GM-CSF and 500 U ml
71 of IL-4. These monocyte-derived DC
were used for surface analysis and mixed lymphocyte reaction.
Flow cytometric analyses
At day 0 of PBMC incubation, 1.0 or 10.0 mgm l
71 of cimetidine
or 0.1 or 1.0 mgm l
71 of famotidine was added to the culture
medium, and at day 7, expression of cell surface molecules asso-
ciated with DC differentiation was analysed using FACScan
(Becton Dickinson, Mountain View, CA, USA) and Cell Quest soft-
ware. The dose of each H2 receptor antagonist (1.0 mgm l
71 of
cimetidine, 0.1 mgm l
71 of famotidine) was based on the EC50,
which denotes the serum concentrations of the drug necessary to
inhibit the pentagastrin-stimulated secretion of acid by 50% (Feld-
man and Burton, 1990). Direct immunoﬂuorescence cell staining
was performed using PE-conjugated anti-CD80 monoclonal anti-
bodies (mAb) (Phar Mingen, San Diego, CA, USA) and PE-conju-
gated isotype control antibodies (Becton Dickinson, San Jose, CA,
USA). Indirect immunoﬂuorescence was performed by staining
with unconjugated anti-CD86 mAb (Ancell, Bayport, MN, USA),
CR3/43 mAb for HLA-DP/DQ/DR (DAKO A/S, Denmark) and
isotype-matched control mAb followed by PE-conjugated F (ab')
two fragments of rabbit anti-mouse IgG/FITC (DAKO A/S,
Denmark) as secondary antibody. Ten thousand cells were analysed
by ﬂow cytometry and the results were presented as the ratio of the
mean channel with cimetidine or famotidine divided by the mean
channel without them.
Allogeneic mixed lymphocyte reactions (allo MLR)
DC of colorectal cancer patients and healthy volunteers were gener-
ated from PBMC as described above. Allogeneic T lymphocytes
were isolated from PBMC of a single healthy volunteer by nylon
ﬁbre non-adherence using T lymphocyte isolation columns (Nylon
Fiber Column T, Wako, Japan). The stimulator cell fractions (DC)
were irradiated with 30 Gy. After extensive washing different
numbers of stimulators were added to the culture wells containing
a ﬁxed amount of T lymphocytes (10
5 well
71) so that the ﬁnal
stimulator to responder ratio (R/S ratio) ranged from 20/1 to
80/1. At day 0 of coculture, 1.0 mgm l
71 of cimetidine or
0.1 mgm l
71 of famotidine was added to the culture medium.
During the last 8 h of 5 days of culture, 1 mCi well
71 [
3H]thymi-
dine (Amersham Pharmacia Biotech, UK) was added. Cells were
then harvested and radioactivity of [
3H]thymidine was measured
with a scintilation counter (Packard, Meriden, CT, USA). The
responses of allogeneic T lymphocytes were expressed as mean
radioactivity (c.p.m.) of [
3H]thymidine incorporated per well.
The stimulation index (S.I) was used to quantify the frequency
of allogeneic T lymphocyte proliferation. The S.I was expressed
as the ratio of c.p.m. with cimetidine or famotidine to c.p.m. with-
out them.
IL-12 assay
DC from colorectal cancer patients and healthy volunteers, and
allogeneic T lymphocytes from a single healthy volunteer were
cocultured at R/S ratio of 10/1 in the presence of 1.0 mgm l
71 of
cimetidine. After 5 days of culture, supernatants were centrifuged
to remove residual cells and stored in 7208C until use. IL-12
p70 heterodimer levels in the supernatants were measured by sand-
wich type enzyme-linked immunosorbent assay (ELISA)
(Immunotech, France) according to the manufacture’s instructions.
All tests were performed in duplicate. The sensitivity levels of the
ELISA assays were 5 pg ml
71.
Statistical analysis
Results were presented as means+standard deviation (s.d.).
Student’s t-test was applied to test signiﬁcant differences and a P
value of 50.05 was considered to indicate statistical signiﬁcance.
All tests were two-tailed.
RESULTS
Effect of cimetidine and famotidine on DC differentiation
Flow cytometry was used to investigate the effect of cimetidine and
famotidine on the differentiation of DC. Expression of MHC–class
II, CD80 and CD86 was analysed and viability of differentiated cells
was measured.
As a result, no enhancing effect of cimetidine on DC differentia-
tion was found. As shown in Table 2, cimetidine slightly increased
the expression of surface molecules only in Case 1, but not in the
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Table 1 Patient characteristics
Case Age
no. (years old) Sex Disease Clinical stage (metastases)
1 57 F Rectal cancer IV (lung, adrenal gland)
2 28 F Colon cancer IV (peritoneum)
3 56 M Rectal cancer IV (liver)
4 42 F Colon cancer IV (liver)
5 60 F Rectal cancer IV (peritoneum)
6 65 F Colon cancer IV (liver)
7 53 M Colon cancer IV (brain)
8 60 M Colon cancer IV (liver)
9 46 F Colon cancer IV (ovary, bone)
10 39 M Colon cancer IV (lung)
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tive data were not found after Case 2. Famotidine showed no
effects in any cases tested (data not shown). Similar results were
obtained in healthy volunteers (data not shown) or at increasing
concentrations (5-, 10-, 50-fold) of each H2 receptor antagonist
(data not shown). These results were substantiated by the fact that
both cimetidine and famotidine did not enhance the viability of
differentiated cells (data not shown).
Effect of cimetidine and famotidine on antigen presenting
capacity of DC
Allo MLR was carried out to investigate the effect of cimetidine
and famotidine on the antigen presenting capacity of DC, and
[
3H]thymidine incorporation of allogeneic T lymphocytes was
measured. Monocyte-derived DC generated as described in Materi-
als and Methods were cocultured with allogeneic T lymphocytes
from a single healthy volunteer in the presence of 1.0 mgm l
71
cimetidine or 0.1 mgm l
71 famotidine.
As a result, in eight out of 10 colorectal cancer patients, cimeti-
dine obviously increased [
3H]thymidine incorporation of allogeneic
T lymphocytes compared to famotidine (Figure 1). In two typical
cases (Case 2 and Case 6), cimetidine increased signiﬁcantly and
constantly [
3H]thymidine incorporation at each R/S ratio of 20/1
to 80/1 (Figure 2). Moreover, mean S.I of cimetidine at each R/S
ratio in all cases was signiﬁcantly higher than that of famotidine
(Figure 3). In a comparison between colorectal cancer patients
and normal controls, cimetidine showed higher increases in the
former than in the latter (P=0.048 at 20/1) (Figure 4). On the
other hand, famotidine did not show any increase both in cancer
patients and normal controls (data not shown).
Effect of cimetidine on IL-12 production of DC
IL-12 concentrations of the supernatants obtained by coculture of
DC with allogeneic T lymphocytes were measured to evaluate the
effect of cimetidine on DC function.
IL-12 production of DC in colorectal cancer patients (n=7) was
slightly lower than in normal controls (n=4). However, although
cimetidine did not affect IL-12 production of DC in normal
controls, it tended to increase IL-12 production in colorectal cancer
patients up to the level of normal controls (P=0.383) (Table 3).
DISCUSSION
The clinical effectiveness of cimetidine against gastrointestinal
malignancies has been reported and various mechanisms of action
have been proposed. In this study, we discovered for the ﬁrst time
the possibility that cimetidine may increase the antigen presenting
capacity of monocyte-derived DC from advanced colorectal cancer
patients although it does not enhance their differentiation. These
results suggest that cimetidine enhances antitumour cell-mediated
immune response by stimulating DC to activate Th1 type immune
response and subsequent CTL induction. Gifford and Tirberg
(1987) demonstrated that cimetidine increased IL-2 production
from mitogen-activated murine spleen cells and this effect might
be due to stimulation of helper T lymphocytes by antigen present-
ing cells. The present results support their ﬁndings.
Our observation that cimetidine increased the antigen presenting
capacity of DC from colorectal cancer patients compared to DC
from normal controls implies improvement of suppressed DC
function in immunosuppressed cancer patients by cimetidine.
Dysfunction of DC in advanced cancer patients is predictable
and Ninomiya et al (1999) have demonstrated that DC from hepa-
tocellular carcinoma had signiﬁcantly lower capacity to stimulate
allogeneic T lymphocytes in allo MLR compared to DC from
normal controls. The stimulatory effect of cimetidine on T
lymphocytes is well-known (Rocklin, 1976; Gifford et al, 1980),
however, it is unlikely that the difference of [
3H]thymidine incor-
poration between cancer patients and normal controls is caused
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Table 2 Effect of cimetidine on DC differentiation
Class II CD80 CD86
Case *C 1.0 C 10 C 1.0 C 10 C 1.0 C 10 Enhancement
1 1.29 1.70 1.12 1.05 1.31 2.43 Yes
2 0.59 0.85 0.94 1.01 0.88 0.87 No
3 1.17 0.90 0.97 0.94 1.03 1.14 No
4 0.94 0.93 1.08 0.86 0.94 1.31 No
5 0.96 0.99 0.77 0.82 0.88 0.70 No
6N D N D N D –
7N D N D N D –
8N D N D N D –
9N D N D N D –
10 ND ND ND –
*C 1.0: Cimetidine 1.0 mgm l
71; C 10: Cimetidine 10 mgm l
71; ND: not done; Mean
channel ratio; Mean channel of C 1.0/mean channel of C 0; Mean channel of C 10/
mean channel of C 0. The expression of MHC-class II, CD80 and CD86 are analysed
by ﬂow cytometry. Data are presented as mean channel ratio as described.
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Figure 1 Antigen presenting capacity of two typical cases (Case 2 and Case 6). Data are presented as amounts (c.p.m.) of [
3H]thymidine incorporation.
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lymphocytes from a single healthy volunteer were used as respon-
ders in allo MLR.
To conﬁrm the hypothesis that cimetidine gives a direct action
to DC themselves and improve the antigen presenting capacity of
DC from colorectal cancer patients, we measured IL-12 in the
supernatants of allo MLR. IL-12 is well known as a cytokine that
is produced by DC responding to antigen stimulation and acts
CD4+ helper T lymphocytes to induce Th1-type immune
responses (Banchereau and Steinman, 1998). The present results
indicate that IL-12 was produced from DC stimulated by allo-
geneic T lymphocytes and cimetidine might improve the
suppressed DC function of colorectal cancer patients. Therefore,
we conclude that the increase of [
3H]thymidine incorporation in
allo MLR may be due to some effects of cimetidine on not only
T lymphocytes but also DC themselves or the interaction between
DC and T lymphocytes.
On the other hand, famotidine, another H2 receptor antago-
nist, did not show the same effects as cimetidine. Because
famotidine behaves as a speciﬁc H2 receptor antagonist with a
molar potency four to eight times greater than that of cimeti-
dine (Peden et al, 1982; Feldman and Burton, 1990), it is
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Figure 3 Comparison of mean S.I with cimetidine and famotidine at R/S
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Figure 4 Comparison of mean S.I with colorectal cancer patients and
normal controls at R/S ratio of 20/1 * 80/1.
Table 3 IL-12 production by allo MLR
Cimetidine (mgm l
71) IL-12 (pg ml
71)
Normal controls (n=4) 0 46.7+1.6
1.0 47.5+3.4
Colorectal cancer patients (n=7) 0 43.4+1.7
1.0 47.3+3.6
Comparison of IL-12 production by all MLR with colorectal cancer patients and
normal controls. Data are presented as means+s.d.
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the effect of cimetidine is mediated via H2 receptors. In this
regard, cimetidine has been reported to have better cell-
mediated immunomodulation (e.g. proliferation and cytotoxicity
of lymphocytes) or histamine (or H2 receptor)-dependent inhi-
bitory effects on tumour growth than other H2 receptor
antagonists such as famotidine and ranitidine, and the differ-
ences between cimetidine and other H2 receptor antagonists
might be due to their structures and/or afﬁnities to H2 recep-
tors (Morris and Adams, 1995; Lawson et al, 1996).
Kobayashi et al (2000) showed that cimetidine can block the
adhesion of colorectal cancer cells to the endothelial cells,
suppressing the metastases of cancer cells. They also considered
that these actions of cimetidine are not mediated via H2 recep-
tors, because other H
2 receptor antagonists, famotidine and
ranitidine, did not show a similar effect. While it remains
unclear whether H2 receptors are expressed on DC or not,
the effect of cimetidine on the antigen presenting capacity of
DC appears to arise because of cimetidine-speciﬁc actions.
Although it remains unclear whether or not the modulating
effects of cimetidine on DC function observed in our investiga-
tion in vitro have clinically substantial meanings, clinical
effectiveness of cimetidine against gastrointestinal malignancies
are considered to be due to the total of immunological and
non-immunological actions of cimetidine.
Finally, both tumour-antigen-speciﬁc and non-speciﬁc immu-
nosuppression have been observed in the tumour-bearing host
(Roth, 1983; Ninomiya et al, 1999). Therefore, immunostimula-
tion offers theoretical beneﬁts for immunotherapy. Further
investigation into DC functions is promising in the search for
more clinically effective tumour-antigen-speciﬁc immunotherapy
and also for the elucidation, of immunosuppressive mechanisms
in tumour-bearing hosts.
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